Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas

• Published in: Virchows Archiv : an international journal of pathology Vol. 476; no. 6; pp. 891 - 902
• Main Authors: Alame, Melissa, Pirel, Marion, Costes-Martineau, Valérie, Bauchet, Luc, Fabbro, Michel, Tourneret, Alicia, De Oliveira, Laura, Durand, Luc, Roger, Pascal, Gonzalez, Samia, Cacheux, Valère, Rigau, Valérie, Szablewski, Vanessa
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2020; Springer Nature B.V; Springer Verlag
• Subjects: Apoptosis; B-cell lymphoma; Cancer; CD163 antigen; CD3 antigen; CD4 antigen; CD8 antigen; Cell death; Central nervous system; Composition; Crosstalk; Cytogenetics; Fluorescence; Fluorescence in situ hybridization; Human health and pathology; Immune checkpoint; Immunohistochemistry; Life Sciences; Lymphocytes; Lymphocytes B; Lymphoma; Macrophages; Medical prognosis; Medicine; Medicine & Public Health; Nervous system; Original Article; Pathogenesis; Pathology; Pax5 protein; PD-1 protein; PD-L1 protein; Quality in Pathology; Translocation; Tumor microenvironment; Tumors; Primary central nervous system diffuse large B cell lymphoma; Immune checkpoints; PDL1; Tumour microenvironment
• ISSN: 0945-6317; 1432-2307
• DOI: 10.1007/s00428-019-02695-6

Primary central nervous system diffuse large B cell lymphoma (PCNS-DLBCL) is a rare and aggressive entity of diffuse large B cell lymphoma (DLBCL). Elements of the tumour microenvironment (TME) including tumour-infiltrating lymphocytes (TILs) and tumour-associated macrophages (TAMs) have been associated with survival in DLBCL but their composition and prognostic impact in PCNS-DLBCL are unknown. Programmed cell death-1 (PD1)/programmed death-ligand 1 (PD-L1) immune checkpoint may represent a therapeutic option. Here, we aimed to characterise PD1/PDL1 immune checkpoints and the composition of the TME in PCNS-DLBCL. We collected tumour tissue and clinical data from 57 PCNS-DLBCL and used immunohistochemistry to examine TAMs (CD68, CD163), TILs (CD3, CD4, CD8, PD1) and tumour B cells (PAX5/PDL1 double stains, PDL1). The PDL1 gene was evaluated by fluorescence in situ hybridization (FISH). PAX5/PDL1 identified PDL1 expression by tumour B cells in 10/57 cases (17.5%). PDL1 gene translocation was a recurrent cytogenetic alteration in PNCS-DLBCL (8/47.17%) and was correlated with PDL1 positive expression in tumour B cells. The TME consisted predominantly of CD163 (+) M2 TAMs and CD8 (+) TILs. Most TAMs expressed PDL1 and most TILs expressed PD1. The density of TAMs and TILs did not associate with outcome. We showed that expression of PD1 on TILs and PDL1 on TAMs, but not the expression of PDL1 on tumour B cells was correlated with better prognosis. These findings support a significant role of TME composition and PD1/PDL1 crosstalk in PCNS-DLBCL pathogenesis and bring new insights to the targeted therapy of this aggressive lymphoma.